MovDisordV3, PascalFrancis, Curation, bibRecord, 000311

Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study

Identifieur interne : 000311 ( PascalFrancis/Curation ); précédent : 000310; suivant : 000312

Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study

Auteurs : Paolo Del Dotto [Italie] ; Nicola Pavese [Italie] ; Gianna Gambaccini [Italie] ; Silvia Bernardini [Italie] ; Leonard Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] ; Ubaldo Bonuccelli [Italie]

Source :

Movement disorders [ 0885-3185 ] ; 2001.

RBID : Pascal:01-0376775

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Dyskinésie, Amantadine, Voie intraveineuse, Lévodopa, Antiparkinsonien, Chimiothérapie, Traitement, Homme, Etude double insu.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Amantadine, Antiparkinson agent, Chemotherapy, Double blind study, Dyskinesia, Human, Intravenous administration, Levodopa, Parkinson disease, Treatment.

Abstract

Experimental evidence suggests that glutamatergic receptor blockade may improve the motor response complications associated with long-term levodopa treatment in Parkinson's disease (PD) patients. Our objective was to evaluate the acute effect of amantadine, a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, on levodopa-induced dyskinesias, and to gain further insights into the antidyskinetic mechanism of this drug. Nine PD patients with motor fluctuations and severely disabling peak of dose dyskinesias received their first morning levodopa dose, followed by a 2-hour intravenous amantadine (200 mg) or placebo infusion, on two different days. Parkinsonian symptoms and dyskinesias were assessed every 15 minutes during the infusion and for 3 hours thereafter, while patients were taking their usual oral antiparkinsonian therapy, by means of Unified Parkinson's Disease Rating Scale (UPDRS, motor examination), tapping test, and a modified Abnormal Involuntary Movement Scale (AIMS). Intravenous amantadine acutely improved levodopa-induced dyskinesias by 50%without any loss of the anti-parkinsonian benefit from levodopa. This study confirms the antidyskinetic effect of amantadine and strengthens the rationale for using antiglutamatergic drugs in the treatment of parkinsonian motor fluctuations.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 16`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study`
A11	`01`	`1`		`@1 DEL DOTTO (Paolo)`
A11	`02`	`1`		`@1 PAVESE (Nicola)`
A11	`03`	`1`		`@1 GAMBACCINI (Gianna)`
A11	`04`	`1`		`@1 BERNARDINI (Silvia)`
A11	`05`	`1`		`@1 VERHAGEN METMAN (Leonard)`
A11	`06`	`1`		`@1 CHASE (Thomas N.)`
A11	`07`	`1`		`@1 BONUCCELLI (Ubaldo)`
A14	`01`			`@1 Department of Neuroscience, Neurology Section, University of Pisa @2 Pisa @3 ITA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 7 aut.`
A14	`02`			`@1 Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health @2 Bethesda, Maryland @3 USA @Z 5 aut. @Z 6 aut.`
A20				`@1 515-520`
A21				`@1 2001`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000099011180170`
A44				`@0 0000 @1 © 2001 INIST-CNRS. All rights reserved.`
A45				`@0 28 ref.`
A47	`01`	`1`		`@0 01-0376775`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Experimental evidence suggests that glutamatergic receptor blockade may improve the motor response complications associated with long-term levodopa treatment in Parkinson's disease (PD) patients. Our objective was to evaluate the acute effect of amantadine, a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, on levodopa-induced dyskinesias, and to gain further insights into the antidyskinetic mechanism of this drug. Nine PD patients with motor fluctuations and severely disabling peak of dose dyskinesias received their first morning levodopa dose, followed by a 2-hour intravenous amantadine (200 mg) or placebo infusion, on two different days. Parkinsonian symptoms and dyskinesias were assessed every 15 minutes during the infusion and for 3 hours thereafter, while patients were taking their usual oral antiparkinsonian therapy, by means of Unified Parkinson's Disease Rating Scale (UPDRS, motor examination), tapping test, and a modified Abnormal Involuntary Movement Scale (AIMS). Intravenous amantadine acutely improved levodopa-induced dyskinesias by 50%without any loss of the anti-parkinsonian benefit from levodopa. This study confirms the antidyskinetic effect of amantadine and strengthens the rationale for using antiglutamatergic drugs in the treatment of parkinsonian motor fluctuations.
C02	`01`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Dyskinésie @5 04`
C03	`02`	`X`	`ENG`	`@0 Dyskinesia @5 04`
C03	`02`	`X`	`SPA`	`@0 Disquinesia @5 04`
C03	`03`	`X`	`FRE`	`@0 Amantadine @2 NK @2 FR @5 07`
C03	`03`	`X`	`ENG`	`@0 Amantadine @2 NK @2 FR @5 07`
C03	`03`	`X`	`SPA`	`@0 Amantadina @2 NK @2 FR @5 07`
C03	`04`	`X`	`FRE`	`@0 Voie intraveineuse @5 10`
C03	`04`	`X`	`ENG`	`@0 Intravenous administration @5 10`
C03	`04`	`X`	`SPA`	`@0 Vía intravenosa @5 10`
C03	`05`	`X`	`FRE`	`@0 Lévodopa @5 13`
C03	`05`	`X`	`ENG`	`@0 Levodopa @5 13`
C03	`05`	`X`	`SPA`	`@0 Levodopa @5 13`
C03	`06`	`X`	`FRE`	`@0 Antiparkinsonien @5 14`
C03	`06`	`X`	`ENG`	`@0 Antiparkinson agent @5 14`
C03	`06`	`X`	`SPA`	`@0 Antiparkinsoniano @5 14`
C03	`07`	`X`	`FRE`	`@0 Chimiothérapie @5 16`
C03	`07`	`X`	`ENG`	`@0 Chemotherapy @5 16`
C03	`07`	`X`	`SPA`	`@0 Quimioterapia @5 16`
C03	`08`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`08`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`08`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`09`	`X`	`FRE`	`@0 Homme @5 20`
C03	`09`	`X`	`ENG`	`@0 Human @5 20`
C03	`09`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`10`	`X`	`FRE`	`@0 Etude double insu @5 23`
C03	`10`	`X`	`ENG`	`@0 Double blind study @5 23`
C03	`10`	`X`	`SPA`	`@0 Estudio doble ciego @5 23`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`06`	`X`	`FRE`	`@0 Trouble neurologique @5 46`
C07	`06`	`X`	`ENG`	`@0 Neurological disorder @5 46`
C07	`06`	`X`	`SPA`	`@0 Trastorno neurológico @5 46`
C07	`07`	`X`	`FRE`	`@0 Mouvement involontaire @5 47`
C07	`07`	`X`	`ENG`	`@0 Involuntary movement @5 47`
C07	`07`	`X`	`SPA`	`@0 Movimiento involuntario @5 47`
C07	`08`	`X`	`FRE`	`@0 Voie administration @5 61`
C07	`08`	`X`	`ENG`	`@0 Route of administration @5 61`
C07	`08`	`X`	`SPA`	`@0 Vía administración @5 61`
N21				`@1 267`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002A10

Links to Exploration step

Pascal:01-0376775

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study</title>
<author><name sortKey="Del Dotto, Paolo" sort="Del Dotto, Paolo" uniqKey="Del Dotto P" first="Paolo" last="Del Dotto">Paolo Del Dotto</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, Neurology Section, University of Pisa</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Pavese, Nicola" sort="Pavese, Nicola" uniqKey="Pavese N" first="Nicola" last="Pavese">Nicola Pavese</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, Neurology Section, University of Pisa</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Gambaccini, Gianna" sort="Gambaccini, Gianna" uniqKey="Gambaccini G" first="Gianna" last="Gambaccini">Gianna Gambaccini</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, Neurology Section, University of Pisa</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Bernardini, Silvia" sort="Bernardini, Silvia" uniqKey="Bernardini S" first="Silvia" last="Bernardini">Silvia Bernardini</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, Neurology Section, University of Pisa</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Verhagen Metman, Leonard" sort="Verhagen Metman, Leonard" uniqKey="Verhagen Metman L" first="Leonard" last="Verhagen Metman">Leonard Verhagen Metman</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, Neurology Section, University of Pisa</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">01-0376775</idno>
<date when="2001">2001</date>
<idno type="stanalyst">PASCAL 01-0376775 INIST</idno>
<idno type="RBID">Pascal:01-0376775</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002A10</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000311</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study</title>
<author><name sortKey="Del Dotto, Paolo" sort="Del Dotto, Paolo" uniqKey="Del Dotto P" first="Paolo" last="Del Dotto">Paolo Del Dotto</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, Neurology Section, University of Pisa</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Pavese, Nicola" sort="Pavese, Nicola" uniqKey="Pavese N" first="Nicola" last="Pavese">Nicola Pavese</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, Neurology Section, University of Pisa</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Gambaccini, Gianna" sort="Gambaccini, Gianna" uniqKey="Gambaccini G" first="Gianna" last="Gambaccini">Gianna Gambaccini</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, Neurology Section, University of Pisa</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Bernardini, Silvia" sort="Bernardini, Silvia" uniqKey="Bernardini S" first="Silvia" last="Bernardini">Silvia Bernardini</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, Neurology Section, University of Pisa</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Verhagen Metman, Leonard" sort="Verhagen Metman, Leonard" uniqKey="Verhagen Metman L" first="Leonard" last="Verhagen Metman">Leonard Verhagen Metman</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, Neurology Section, University of Pisa</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2001">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amantadine</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Double blind study</term>
<term>Dyskinesia</term>
<term>Human</term>
<term>Intravenous administration</term>
<term>Levodopa</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Dyskinésie</term>
<term>Amantadine</term>
<term>Voie intraveineuse</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Homme</term>
<term>Etude double insu</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Experimental evidence suggests that glutamatergic receptor blockade may improve the motor response complications associated with long-term levodopa treatment in Parkinson's disease (PD) patients. Our objective was to evaluate the acute effect of amantadine, a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, on levodopa-induced dyskinesias, and to gain further insights into the antidyskinetic mechanism of this drug. Nine PD patients with motor fluctuations and severely disabling peak of dose dyskinesias received their first morning levodopa dose, followed by a 2-hour intravenous amantadine (200 mg) or placebo infusion, on two different days. Parkinsonian symptoms and dyskinesias were assessed every 15 minutes during the infusion and for 3 hours thereafter, while patients were taking their usual oral antiparkinsonian therapy, by means of Unified Parkinson's Disease Rating Scale (UPDRS, motor examination), tapping test, and a modified Abnormal Involuntary Movement Scale (AIMS). Intravenous amantadine acutely improved levodopa-induced dyskinesias by 50%without any loss of the anti-parkinsonian benefit from levodopa. This study confirms the antidyskinetic effect of amantadine and strengthens the rationale for using antiglutamatergic drugs in the treatment of parkinsonian motor fluctuations.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>16</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>DEL DOTTO (Paolo)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>PAVESE (Nicola)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>GAMBACCINI (Gianna)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BERNARDINI (Silvia)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>VERHAGEN METMAN (Leonard)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>CHASE (Thomas N.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>BONUCCELLI (Ubaldo)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neuroscience, Neurology Section, University of Pisa</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>515-520</s1>
</fA20>
<fA21><s1>2001</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000099011180170</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2001 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>28 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>01-0376775</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Experimental evidence suggests that glutamatergic receptor blockade may improve the motor response complications associated with long-term levodopa treatment in Parkinson's disease (PD) patients. Our objective was to evaluate the acute effect of amantadine, a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, on levodopa-induced dyskinesias, and to gain further insights into the antidyskinetic mechanism of this drug. Nine PD patients with motor fluctuations and severely disabling peak of dose dyskinesias received their first morning levodopa dose, followed by a 2-hour intravenous amantadine (200 mg) or placebo infusion, on two different days. Parkinsonian symptoms and dyskinesias were assessed every 15 minutes during the infusion and for 3 hours thereafter, while patients were taking their usual oral antiparkinsonian therapy, by means of Unified Parkinson's Disease Rating Scale (UPDRS, motor examination), tapping test, and a modified Abnormal Involuntary Movement Scale (AIMS). Intravenous amantadine acutely improved levodopa-induced dyskinesias by 50%without any loss of the anti-parkinsonian benefit from levodopa. This study confirms the antidyskinetic effect of amantadine and strengthens the rationale for using antiglutamatergic drugs in the treatment of parkinsonian motor fluctuations.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Amantadine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Amantadine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Amantadina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Voie intraveineuse</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Intravenous administration</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Vía intravenosa</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>13</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>13</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>14</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>14</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Etude double insu</s0>
<s5>23</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Double blind study</s0>
<s5>23</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Estudio doble ciego</s0>
<s5>23</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>46</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>46</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>46</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>47</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>47</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>47</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Voie administration</s0>
<s5>61</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Route of administration</s0>
<s5>61</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Vía administración</s0>
<s5>61</s5>
</fC07>
<fN21><s1>267</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000311 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000311 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:01-0376775
   |texte=   Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study

Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri